KNTE - Why Is Cancer Firm Kinnate Biopharma Stock Trading Lower Today? | Benzinga
Kinnate Biopharma Inc (NASDAQ: KNTE) announced pipeline updates, a reprioritization plan, and workforce restructuring to extend the cash runway.
The company is prioritizing the exarafenib combination, KIN-8741, and discovery efforts around its CDK4 selective program.
Additionally, Kinnate will pause the development of KIN-7136 and explore strategic alternatives for exarafenib monotherapy and KIN-3248 as part of the reprioritization plan.
As of September 18, 2023, exarafenib plus binimetinib was generally well-tolerated ...